Stock A041910 POLARIS AI PHARMA CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Polaris AI Pharma Corp.

Equities

A041910

KR7041910001

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
9,110 KRW -2.04% Intraday chart for Polaris AI Pharma Corp. -6.28% +32.03%
Mar. 27 Polaris Office Corp., Leenos Corp., Sewon Co.,Ltd and POLARIS UNO, Inc. completed the acquisition of 20% stake in EstechPharma Co., Ltd. from Jae-cheol Kim and Seon-hee Bae. CI
Feb. 29 Polaris Office Corp., Leenos Corp., Sewon Co.,Ltd and POLARIS UNO, Inc. agreed to acquire 20% stake in EstechPharma Co., Ltd. from Jae-cheol Kim and Seon-hee Bae for KRW 40 billion. CI

Valuation

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Capitalization 1 120,589 141,007 96,243 122,056 147,752 112,128
Enterprise Value (EV) 1 113,059 125,539 72,316 82,379 99,395 61,446
P/E ratio 30.5 x 93.8 x 14.8 x 8.02 x 13.5 x 16.3 x
Yield 0.47% 0.41% 0.61% 0.96% 0.79% 1.04%
Capitalization / Revenue 2.78 x 3.69 x 2.39 x 2.63 x 2.41 x 1.86 x
EV / Revenue 2.61 x 3.29 x 1.79 x 1.77 x 1.62 x 1.02 x
EV / EBITDA 15.9 x 18.7 x 16.9 x 12.7 x 9.11 x 8.93 x
EV / FCF 22.1 x 24 x 13 x 20.2 x 114 x -31.1 x
FCF Yield 4.53% 4.17% 7.72% 4.95% 0.87% -3.21%
Price to Book 1.55 x 1.68 x 1.08 x 1.19 x 1.33 x 0.91 x
Nbr of stocks (in thousands) 11,323 11,558 11,680 11,680 11,680 11,680
Reference price 2 10,650 12,200 8,240 10,450 12,650 9,600
Announcement Date 3/15/17 3/19/18 3/19/19 3/16/20 3/16/21 3/23/22
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net sales 1 43,397 38,214 40,336 46,490 61,324 60,401
EBITDA 1 7,107 6,725 4,288 6,475 10,908 6,879
EBIT 1 2,775 2,535 1,550 3,728 8,234 4,205
Operating Margin 6.39% 6.63% 3.84% 8.02% 13.43% 6.96%
Earnings before Tax (EBT) 1 4,540 1,163 7,965 19,056 13,286 7,773
Net income 1 4,148 1,514 6,590 15,228 10,957 6,875
Net margin 9.56% 3.96% 16.34% 32.76% 17.87% 11.38%
EPS 2 349.0 130.0 557.0 1,304 938.0 588.6
Free Cash Flow 1 5,117 5,230 5,584 4,074 868.6 -1,974
FCF margin 11.79% 13.69% 13.84% 8.76% 1.42% -3.27%
FCF Conversion (EBITDA) 71.99% 77.77% 130.21% 62.92% 7.96% -
FCF Conversion (Net income) 123.36% 345.37% 84.73% 26.75% 7.93% -
Dividend per Share 2 50.00 50.00 50.00 100.0 100.0 100.0
Announcement Date 3/15/17 3/19/18 3/19/19 3/16/20 3/16/21 3/23/22
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net Debt 1 - - - - - -
Net Cash position 1 7,530 15,468 23,927 39,677 48,357 50,682
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 5,117 5,230 5,584 4,074 869 -1,974
ROE (net income / shareholders' equity) 5.55% 1.88% 7.68% 15.9% 10.2% 5.74%
ROA (Net income/ Total Assets) 1.84% 1.63% 1% 2.17% 4.3% 1.99%
Assets 1 225,806 92,881 657,588 701,847 255,054 344,723
Book Value Per Share 2 6,861 7,256 7,641 8,795 9,537 10,556
Cash Flow per Share 2 1,814 1,857 2,049 3,345 3,533 3,956
Capex 1 1,643 692 466 1,125 2,199 1,998
Capex / Sales 3.79% 1.81% 1.16% 2.42% 3.59% 3.31%
Announcement Date 3/15/17 3/19/18 3/19/19 3/16/20 3/16/21 3/23/22
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
POLARIS AI PHARMA CORP. Stock Polaris AI Pharma Corp.
+32.03% 77.94M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.51% 727B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+33.05% 599B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.23% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.78% 328B
ABBVIE INC. Stock AbbVie Inc.
+1.35% 277B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.00% 243B
NOVARTIS AG Stock Novartis AG
+8.09% 205B
ROCHE HOLDING AG Stock Roche Holding AG
-5.77% 203B
AMGEN INC. Stock Amgen Inc.
+6.19% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A041910 Stock
  4. Financials Polaris AI Pharma Corp.